ATP is a leading life sciences fund with global presence and reach that is developing the next generation of transformative biotechnology companies.
ATP brings together over $2.5 billion under management, one of the sector’s most highly-selective funding methodologies, and a seasoned team of venture partners to create a proven hub-and-spokes model.
ATP works with the world’s most innovative life scientists and provides the capital, expertise, and operational intelligence to build new companies and drive long-term value.
Recent News
-
Dec 08, 2019
Stoke Therapeutics Presents Preclinical Data on the Biodistribution of STK-001
-
Dec 07, 2019
Stoke Therapeutics Presents Preclinical Data From Studies of STK-001
-
Nov 27, 2019
FDA approves system for the delivery of ear tubes under local anesthesia...
-
Nov 25, 2019
New Clinical Results from RheOxTM System for Chronic Bronchitis
-
Nov 25, 2019
FDA Grants Braeburn’s Citizen Petition Allowing BRIXADI
-
Oct 01, 2019
ATP Names Michael Ehlers as Chief Scientific Officer and Venture Partner